Individuals with compromised immunity and persistent COVID-19 infections can harbor drug-resistant variants of the SARS-CoV-2 virus, which have the potential to spread to the general population, ...
Roche RHHBY announced positive top-line results from a late-study on influenza drug, Xofluza. The CENTERSTONE study was a global phase III trial investigating the efficacy of single-dose Xofluza, ...
Individuals with compromised immunity and persistent COVID-19 infections can harbor drug-resistant variants of the SARS-CoV-2 virus, which have the potential to spread to the general population found ...
Xofluza was well tolerated with no new safety signals identified. Every year, seasonal influenza infects an estimated one billion people and causes up to 650,000 deaths globally. On Thursday ...